← All trials
NCT05646511
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 21, 2022
- Primary completion
- Dec 31, 2029
- Completion date
- Dec 31, 2030
- First posted
- Dec 12, 2022
- Last posted
- Dec 13, 2022
- Enrollment
- 608
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Cancer Center, JapanLead sponsor
- National Cancer Center, JapanReponsible party - principal investigator
- Japan Agency for Medical Research and DevelopmentCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.